IPH 1101

Drug Profile

IPH 1101

Alternative Names: IPH-1101; Phosphostim

Latest Information Update: 21 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM
  • Developer Innate Pharma
  • Class Antineoplastics; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cytokine stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia; Follicular lymphoma; Hepatitis C; Malignant melanoma; Renal cancer

Most Recent Events

  • 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Belgium (IV)
  • 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in France (IV)
  • 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top